Skip to content
ParcelBio logo — Elevated mRNA for transformative medicines.

ParcelBio

Elevated mRNA for transformative medicines.

Founded 2024 United States San Francisco, United States 7 employees Total: $130.00K Biopharma, Biotechnology

General Information

Company Name ParcelBio
Founded Year 2024
Location United States San Francisco, United States
Employees 7
Industries Biopharma, Biotechnology
Business Model B2B, D2C, B2D
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with ParcelBio. To contact ParcelBio, visit parcelbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ParcelBio compare?

A PDF of ParcelBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ParcelBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ParcelBio

ParcelBio is a promising player in the Biopharma and Biotechnology industries, founded in 2023. Their mission, encapsulated in their slogan, "Delivering the next generation of RNA medicines," indicates their focus on advancing RNA biotechnology.

Headquartered in the United States, ParcelBio is targeting revolutionary advancements in medicine, potentially placing it at the forefront of the biotech sector. The company's cutting-edge approach to RNA medicines suggests a specialization that could meet significant demand in the medical field.

Their recent $130.00K investment, granted through a Support Program as of 01 March 2024, underscores the confidence that seasoned investors, including Y Combinator, have in the company's potential. Such backing provides ParcelBio not only with capital but valuable market exposure and mentorship, essential for nurturing the startup's ambitious growth trajectory in the competitive biotech landscape.

Business keywords: RNA medicines, mRNA delivery, genomic medicine, programmable delivery, cell targeting, therapeutics, precision medicine, biopharmaceuticals, drug delivery systems, molecular biology, innovative healthcare, gene therapy, next-generation therapeutics, medical innovation

Services & Products

development of RNA-based medicines
advanced therapeutic solutions

Target Customers

medical professionals healthcare institutions patients requiring genetic therapies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Support Program $130.00K 1
Y Combinator
01 Mar 2024

ParcelBio Alternatives & Competitors

View All Alternatives
ParcelBio vs
SonoThera
SonoThera United States

SonoThera is developing ultrasound-mediated nonviral genetic therapies.

Series A
54 employees
Biopharma, Biotechnology
ParcelBio vs

Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions o...

50 employees
Biopharma, Biotechnology
ParcelBio vs

Reprogramming Immunity for Target-Specific Medicines

Seed
7 employees
Biopharma, Biotechnology

FAQ About ParcelBio

Elevated mRNA for transformative medicines.
ParcelBio was founded in 2024.
ParcelBio is headquartered in San Francisco, United States.
ParcelBio operates in Biopharma and Biotechnology. Its work centres on RNA medicines, mRNA delivery, genomic medicine and programmable delivery. Its customers include medical professionals, healthcare institutions and patients requiring genetic therapies.
ParcelBio has a B2B, D2C and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.
ParcelBio has approximately 7 employees.
ParcelBio has completed 1 funding round, raising a total of $130.00K.
ParcelBio offers: development of RNA-based medicines, advanced therapeutic solutions.
Top alternatives and competitors to ParcelBio include SonoThera, Arrakis Therapeutics, Granza Bio, Senolytx, Rampart Bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ParcelBio and SonoThera are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ParcelBio, https://bouncewatch.com/company/parcelbio, updated 17 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout